Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

40,602 stories, page 408 of 677

Advanced search

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FDA Panel Backs Two Peptides For Compounding, Rejects One

U.S. News & World ReportOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

Apnimed aspires for up to $160M IPO as sleep apnea launch nears

Fierce BiotechOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Cspc Pharmaceutical Says Nmpa Accepts New Drug Application For Sirolimus For Injection (Albumin-Bound)

TradingViewOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Capricor Provides Update on Deramiocel for DMD Ahead of FDA Meeting

Intellectia AIOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

4th Circuit could hear NC abortion drug case in October

Carolina JournalOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FDA Panel Backs Two Peptides For Compounding, Rejects One

HealthDayOriginal source

🇺🇰Jul 27Industrygsk.comTier 1 · Company source

ViiV Healthcareâ€™s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV

GSK NewsOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

AstraZeneca’s HSCT-TMA drug misses main endpoint

EMJOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Mid-Year Check-In: Where Is Patient Access Headed?

Pharmaceutical CommerceOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Raymond James cuts Legend Biotech stock price target on CEO departure

Investing.comOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Active Biotech comments on first dose in updated myelofibrosis study

BiostockOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test

Fierce BiotechOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FBRX Stock Extends Rally As Barclays Lifts Biotech Hopes

StocksToTradeOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Earnings Preview: Ono Pharmaceutical Co. (OPHLF) Q1 Earnings Expected to Decline

Yahoo FinanceOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Why is Legend Biotech stock sliding today?

Investing.comOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Pakistan, China Sign $850 Million Deals to Boost Pharmaceutical Cooperation

The Diplomat – Asia-PacificOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Cambridge biotech taps external executive to lead after Elevidys controversy

The Business JournalsOriginal source

🇺🇰Jul 27Regulatorygov.ukTier 1 · Regulatory source

Medicine supply disruption statistics, UK: data to June 2026

Twice-yearly official statistics on medicine supply issue and discontinuation notifications reported...

UK Department of Health and Social CareOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

From confidence to capital: Positioning biotech for the next growth cycle

BioPharma DiveOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

Legend Biotech CEO abruptly steps down without permanent replacement

Fierce PharmaOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Can Takeda Pharmaceutical (TSE:4502) Trade At A Discount On New Phase 3 Psoriasis Data?

simplywall.stOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

Pharmalittle: We're reading about a U.S. peptide panel's votes, Amgen scuffling with the FDA, and more

STATOriginal source

🇺🇰Jul 27Devicespresspart.comTier 1 · Company source

Customer Satisfaction Survey 2026

H&T PresspartOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Crystalys Therapeutics Raises $130 Million Series B, Strengthening Fortress Biotech's Dotinurad Stake

citybizOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FDA Approves First-in-Class Centanafadine for Treatment of ADHD

Drug TopicsOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Vaccines Are Safe. A Worrisome Portion Of Our Generic Drugs Are Not

ForbesOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

STATOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

EIFO invests DKK 20m in biotech firm Quantumcell

medwatch.comOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

IPO News - IPO Winners & Losers: Jersey Mike's, Bubble Baths, and Biotech Wins

renaissancecapital.comOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Ensuring drug quality: mastering stability testing in pharma

European Pharmaceutical ReviewOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Lexicon's HCM study spans 20 countries; results anticipated Q1 2027

Stock TitanOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships

The Manila TimesOriginal source

🇪🇺Jul 27Researchmyesr.orgTier 2 · Direct publisher

Imaging Saves Lives: Report from the European Parliament event on the role of imaging in improving cardiovascular health

European Society of RadiologyOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Lexicon completes enrollment in phase 3 heart disease trial By Investing.com

Investing.com CanadaOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Medicus Pharma Receives FDA 'Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

The Manila TimesOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Compounded GLP-1 drugs creating concern among doctors and FDA

NewsNationOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Veru Inc. Announces Full Enrollment in Phase 2b PLATEAU Trial of Enobosarm in Older Patients With Obesity

Quiver QuantitativeOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome

The Manila TimesOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Medicus Pharma Receives FDA “Study May Proceed” Letter for

GlobeNewswireOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

#Aids2026: Daily pill. Monthly pill. Six-monthly jab. Why choice matters

Mail & GuardianOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FDA Escalates Warnings Over Unregulated Compounded GLP-1 Weight Loss Drugs

streamlinefeed.co.keOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Clinical Trial Per-Patient Cost Analytics For Procurement And Sponsor Strategy

Clinical LeaderOriginal source

🇨🇦Jul 27Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

Sphere-9™ Catheter

There have been forty-six (46) reported incident reports (none of which were from Canada) where pati...

Health Canada Recalls and Safety AlertsOriginal source

🇨🇦Jul 27Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

Spacelabs Healthcare Xhibit® Central Station

Spacelabs Healthcare has concluded that the use of the previously distributed splitter (part number...

Health Canada Recalls and Safety AlertsOriginal source

🇨🇦Jul 27Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

Harmonic Arts Holy Basil Tincture; Out of Specification (total aerobic microbial count)

The total aerobic microbial count is out of specification in the affected lot.

Health Canada Recalls and Safety AlertsOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Asia-Pacific Roundup: TGA adopts 23 international scientific guidelines

RAPSOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing

GlobeNewswireOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Science Spotlight: Taking the Leap to Found a Biotech Startup

CUNY Graduate CenterOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Oak Hill Bio and Research Alliance Corporation III Announce

GlobeNewswireOriginal source

🇺🇸Jul 27CROir.labcorp.comTier 3 · Secondary coverage

Labcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk Testing

Labcorp Drug DevelopmentOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength?

Yahoo FinanceOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FDA panel backs six peptides for pharmacy compounding

Manufacturing ChemistOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Eikon Therapeutics Doses First Patient in Phase 2/3 TeLuRide-008 Trial of EIK1001 for First-Line Stage 4 NSCLC

Quiver QuantitativeOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Wockhardt Gets US FDA Approval for Novel Antibiotic Zaynich

WhalesbookOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

The Manila TimesOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Eikon Doses First Patient in EIK1001 Stage 4 Lung Cancer Study

Stock TitanOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Arrowhead's Rare Cholesterol Disease Study Reaches 70 Patients

Stock TitanOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Business WireOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565

PR NewswireOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It

Yahoo FinanceOriginal source